Adnexal Masses Part III: Germ Cell Tumors

/

Germ cell tumors are our next foray into these adnexal masses. They comprise 20-25% of ovarian neoplasms, can be benign or malignant, and occur generally in younger women: between ages 10-30 years.

Many of these for CREOGs are distinguished by specific tumor markers and specific histopathology. We’ve put a brief table together here to help with the episode and get some of those visual references!

(C) CREOGs Over Coffee (2019)

Adnexal Masses Part II: Epithelial Neoplasms

/

On today’s episode, we start into epithelial neoplasms of the ovary, which comprise about 90% of cancers of the ovary, fallopian tube, and peritoneum. Here are the show notes in outline format!

Benign epithelial  neoplasms 

  1. Serous cystadenoma 

    1. Among the most common benign ovarian neoplasms (20-25%); sized 5-20 cm

    2. Benign, but if persistently symptomatic, can have surgical removal 

    3. There is no good data regarding the decision to observe or remove if they are asymptomatic, but decision to operate may be guided by age, size of mass, ultrasound appearance, family history or other risk factors for ovarian cancer + medical comorbidities 

  2. Mucinous cystadenoma, lining similar to viscera or gastric lining  

    1. <5% of ovarian neoplasms 

    2. Contains mucin 

    3. Treatment same as above 

  1. Borderline ovarian epithelial neoplasms 

    1. Serous borderline neoplasms - most common histologic subtype of borderline tumors and accounts for 65% of all borderline ovarian neoplasms 

      1. Usually confined to the ovary and is slow growing

      2. 10 year survival rate is 95-100%, though late recurrences are not uncommon 

      3. Prognosis is still excellent even if there is presence of peritoneal implants and regional lymph node involvement 

      4. Histology: serous epithelial proliferation; more complex architectural patterns than a serous cystadenoma, and can have areas of microinvasion (area of cells <5 mm that are invading into the stromal core of the papillae or cyst wall); if it’s >5 mm, then it should be classified as a low-grade serous carcinoma 

      5. In fact, serous borderline neoplasms have similar immunophenotype and molecular biology to LGSC and may suggest that LGSC can arise from borderline neoplasms 

      6. Treatment: surgery 

    2. Mucinous borderline neoplasm - nearly always confined to ovary, unlike serous 

      1. Usually appears large, unilateral, multilocular cyst with smooth, white capsule 

      2. Epithelial lining with two general types: GI type and endocervical (or seromucinous) type 

      3. Approximately 10-20% exhibit microinvasion 

      4. Treatment: surgery 

    3. Endometrioid borderline neoplasm - biologic potential between cystadenomas/adneofibromas and invasive endometrioid adenocarcinoma of the ovary 

      1. Uncommon - 2-10% of borderline neoplasms 

      2. General appearance: firm, with smooth surface and multiple small cysts with clear or hemorrhagic fluid  

      3. Histologically, have adenofibromatous pattern with nodular architecture, but more proliferative with appearance similar to complex atypical hyperplasia of the endometrium 

      4. Actually same criteria exist to differentiate it from invasive carcinoma as there is between complex atypical hyperplasia and well-differentiated endometrioid adenocarcinoma of the endometrium 

      5. Microinvasion can be seen 

  2. Carcinomas 

    1. We will talk about staging and treatment in another episode! 

    2. High-grade serous carcinoma (70-80% epithelial carcinomas) 

      1. Most common type of ovarian cancer, and accounts for 70-80% of  all malignant ovarian neoplasms 

      2. Peak age range is 45-65 years; usually diagnosed at advanced stage 

      3. Histologically, HGSC will infiltrate and destroy 

      4. BRCA1 or BRCA2 germline mutations are found in up to 10% of women with HGSC 

      5. Women with these mutations have a 30-50% risk of developing ovarian carcinoma by age 70 

    3. Low-grade serous carcinoma (<5%)

      1. Uncommon 

      2. Typically diagnosed at advanced stage; therefore, long-term prognosis is poor 

      3. Slow-growing, indolent tumors with relative insensitivity to platinum-based chemo 

      4. Can be found alongside noninvasive serous borderline tumors

      5. LGSC differentiated from HGSC by cytologic features; usually have more uniform nuclei, lower mitotic activity; also has numerous psammoma bodies 

    4. Endometrioid carcinoma (10%) 

      1. Unlike serous carcinomas, it is usually identified at an early stage, and therefore, patients have a better prognosis 

      2. Tend to be relatively chemosensitive 

      3. Thought to arise from endometriosis and is associated with carcinoma of the endometrium in 15-20% of cases 

      4. Histologically, this type of carcinoma resembles the uterine counterparts 

    5. Clear cell carcinoma (10%) 

      1. Present most commonly in perimenopausal women in 40s or 50s 

      2. Often presents at an early stage, relatively good prognosis due to absence of distant metastases 

      3. However, if it is present at advanced stage, it has worse prognosis than serous or endometrioid carcinoma, because it is not as sensitive to platinum-based chemo 

      4. Possibly arises from endometriosis 

    6. Mucinous carcinoma (3%)  

      1. Nearly all present in early stages, usually stage I; often seen with borderline neoplasm 

      2. Reason it’s found early is because it is usually large upon discovery: 8-20 cm, but can be even larger

      3. Tends to be cystic or solid, unilateral, and confined to the ovary

      4. There are two patterns of “invasion” - infiltrative invasion and expansile growth pattern

      5. Infiltrative: obvious destructive stromal invasion -  worse prognosis 

      6. Expansile growth pattern: does not demonstrate obvious stromal invasion, but has complex architecture; better prognosis